| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | UTHR | Common Stock | Options Exercise | $666,000 | +6,000 | +16% | $111.00 | 42,487 | 17 Mar 2022 | Direct | F1, F2 |
| transaction | UTHR | Common Stock | Sale | $91,315 | -504 | -1.2% | $181.18 | 41,983 | 17 Mar 2022 | Direct | F1, F3 |
| transaction | UTHR | Common Stock | Sale | $703,986 | -3,865 | -9.2% | $182.14 | 38,118 | 17 Mar 2022 | Direct | F1, F4 |
| transaction | UTHR | Common Stock | Sale | $234,746 | -1,281 | -3.4% | $183.25 | 36,837 | 17 Mar 2022 | Direct | F1, F5 |
| transaction | UTHR | Common Stock | Sale | $64,454 | -350 | -0.95% | $184.15 | 36,487 | 17 Mar 2022 | Direct | F1, F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | UTHR | Stock Options | Options Exercise | $0 | -6,000 | -10% | $0.000000 | 52,552 | 17 Mar 2022 | Common Stock | 6,000 | $111.00 | Direct | F1, F7 |
| Id | Content |
|---|---|
| F1 | This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. |
| F2 | Includes 118 shares acquired on March 4, 2022, under the United Therapeutics Corporation Employee Stock Purchase Plan. |
| F3 | This transaction was executed in multiple trades at prices ranging from $180.56 to $181.465. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| F4 | This transaction was executed in multiple trades at prices ranging from $181.62 to $182.505. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| F5 | This transaction was executed in multiple trades at prices ranging from $182.75 to $183.6375. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| F6 | This transaction was executed in multiple trades at prices ranging from $183.99 to $184.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| F7 | These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021. |